From Yahoo Finance: 2025-06-07 06:30:00

Pfizer’s dividend yield is at 7.3%, with many drugs in development. The company faces challenges but has a low valuation. Pfizer is valued at $133 billion, with 108 candidates in its pipeline. Major medications include the COVID-19 vaccine and treatments for cancer and pneumonia. Pfizer offers a 7.3% dividend yield and growth prospects in oncology. The stock has a low valuation with a forward P/E ratio of 8. Pfizer is facing struggles, including patent expirations and revenue declines. The company is impacted by the ongoing tariff wars and potential policy changes. Analysts suggest buying Pfizer for its dividend yield and growth potential. However, it was not listed among the top 10 stocks by the Motley Fool Stock Advisor team.



Read more at Yahoo Finance: Should You Buy Pfizer Stock Right Now?